Farzin Hak
Analyst
Jefferies
Equibles does not estimate personal net worth.
About Farzin Hak
Farzin Hak is recorded as Analyst at Jefferies. Farzin Hak has spoken on 1 earnings call and 4 other investor events across 4 companies, most recently for Black Diamond Therapeutics, Inc. on November 19, 2026. Those appearances were for Relmada Therapeutics, Inc. (RLMD), Black Diamond Therapeutics, Inc. (BDTX), Nuvation Bio Inc. (NUVB) and Pyxis Oncology, Inc. (PYXS). The companies whose calls Farzin Hak spoke on are classified in the Healthcare sector.
Farzin Hak on recent calls
“It's my pleasure to introduce Mark Valleca, CEO of Black Diamond Therapeutics. Thank you for joining us today. Maybe to start off with a quick overview of the company, and then we can dig into the very specific eventful week we had last week on the clinical and regulatory update.”
“It's my pleasure to introduce David Haak, CEO, and Philip Sabaj, CFO of Innovation Bio. Maybe, David, you can start off giving a quick one-minute intro to the company.”
“It's my pleasure to introduce Sergio Traversa, BP in Dalmia, and Maggie Shinodia of RealMada. So this is the Fireside Chat format. Maybe to start off, Sergio, can you provide a brief intro to the company?”
“It's my pleasure to introduce Tom Civic, CEO of Pixis Oncology. This is a fireside chat format. Thank you for joining us today, Tom.”
“So following up on an earlier question, like you have a broad inclusion criteria for phase three, the BCG and responsive setting, and you're allowing up to two prior lines, including a wide-range start 200 in Lexa, et cetera.”
Affiliation history
-
Jefferies
Analyst
Transcript header (unverified)
Current
Company network
Nuvation Bio Inc.
NUVB
Biotechnology · Healthcare
1 appearance
Latest appearance 2026-11-17
View calls and events
Pyxis Oncology, Inc.
PYXS
Biotechnology · Healthcare
1 appearance
Latest appearance 2026-06-04
View calls and events